Xiaorong Y. Dong

Union Hospital
Wuhan, 430023, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 194 publications

Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer.

Dosimetric impact of spatial separation in combined SBRT and mediastinal radiotherapy for peripheral small cell lung cancer.

Journal: International journal of radiation biology

Published: August 07, 2026

Construction of a regulated Crat overexpression system in mouse hippocampal neuronal HT22 cell line

Construction of a regulated Crat overexpression system in mouse hippocampal neuronal HT22 cell line

Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Published: June 30, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

Octahedral Ni3+ Substitution-Induced D-Band Center Modulation Enables Fast and Fully Reversible Conversion Kinetics in Spinel Sulfide Anodes for Sodium Storage.

Octahedral Ni3+ Substitution-Induced D-Band Center Modulation Enables Fast and Fully Reversible Conversion Kinetics in Spinel Sulfide Anodes for Sodium Storage.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: May 13, 2026

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.

Journal: Future oncology (London, England)

Published: April 27, 2026

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription.

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 19, 2026

Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial.

Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial.

Journal: Clinical lung cancer

Published: March 20, 2026

Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy.

Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy.

Journal: Frontiers in immunology

Published: March 17, 2026

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 06, 2026

The discourse and prospect of traditional Chinese medicine in the perspective of social and cultural history

The discourse and prospect of traditional Chinese medicine in the perspective of social and cultural history

Journal: Zhonghua yi shi za zhi (Beijing, China : 1980)

Published: February 05, 2026

Tailoring Solvation Structure via Soft-Hard Segment Synergy in Gel Polymer Electrolytes Enables Dendrite-Free Sodium Batteries with Ultra-Long Cycling.

Tailoring Solvation Structure via Soft-Hard Segment Synergy in Gel Polymer Electrolytes Enables Dendrite-Free Sodium Batteries with Ultra-Long Cycling.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: February 03, 2026

SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China.

SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 23, 2025

Showing 1-12 of 194

Last Updated: 09/26/2026